ALX ONCOLOGY HOLDINGS INC (ALXO) — insider trading
Health Care · NASDAQ
ALX ONCOLOGY HOLDINGS INC (ALXO) has 10 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 4 open-market sales among the most recent 10 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Wong Shelly | Officer (SVP, FINANCE AND CAO) | Open-market sale | 1,404 | $2.04 | $2.9K | Form 4 |
| 2026-04-16 | Klencke Barbara | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 100,000 | $0.00 | $0 | Form 4 |
| 2026-04-16 | Knight Jeff E. | Officer (Chief Dev & Operating Officer) | Grant / award / vesting (derivative) | 800,000 | $0.00 | $0 | Form 4 |
| 2026-03-19 | Pinto Shelly | Officer (SVP, FINANCE AND CAO) | Open-market sale | 903 | $2.17 | $2.0K | Form 4 |
| 2026-03-19 | Lettmann Jason | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 12,311 | $2.17 | $26.7K | Form 4 |
| 2026-03-03 | Klencke Barbara | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 700,000 | $0.00 | $0 | Form 4 |
| 2026-02-18 | Pinto Shelly | Officer (SVP, FINANCE AND CAO) | Open-market sale | 565 | $2.27 | $1.3K | Form 4 |
| 2026-02-17 | Lettmann Jason | Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for taxes / exercise cost | 2,201 | $2.27 | $5.0K | Form 4 |
| 2026-02-02 | GOODMAN COREY S | Director, 10% owner | Open-market purchase | 3,184,713 | $1.57 | $5.00M | Form 4 |
| 2026-01-26 | Shantharam Harish | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 303,000 | $0.00 | $0 | Form 4 |
Ask the chat about ALXO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ALX ONCOLOGY HOLDINGS INC (ALXO).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.